Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PAGSEG Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while PAGSEG Inc trades at $9.38 (market cap $2.59B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 15.4× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.24% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PAGS | |
|---|---|---|
Market Cap | $39.89B | $2.59B |
Sector | Health | Technology |
52-Week High | $491.22 | $12.00 |
52-Week Low | $278.09 | $7.75 |
Enterprise Value | $38.15B | $10.22B |
Dividend Yield | — | 11.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PAGS trades at $9.25, up 2.78% with neutral technical indicators showing support at $9 and resistance at $9. The stock presents strong value fundamentals with a P/E of 6.55 and P/B of 0.92, supported by solid profitability including 10.4% net margins and 14.52% ROE. Recent earnings showed mixed results with a Q1 2026 miss but Q4 2025 beat, while the company maintains robust cash flow generation of $7.56B from operations.
The investment case centers on deep valuation discounts and Brazil's rate-cutting cycle potential, though execution risks and competitive pressures remain. Analyst consensus is strongly bullish with 62.5% buy ratings, viewing current levels as attractive for long-term investors given the company's banking and credit expansion trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
